IDH2 and central nervous system cancer: Additionally, methylation in MGMT promoter [4], deletion in chromosome 1p and 19q [5], and isocitrate dehydrogenase (IDH) 1 and IDH2 mutations [6] are used for diagnosing or treating patients with glioma.